Q3 2023 · 13F-HR
Bain Capital Life Sciences Investors, LLCholdings as filed
Filed 2023-11-14 · accession 0000950123-23-010856
$894.2M
Reported value
31
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 670703107 | NUVL | NUVALENT INC | $164.4M | 18.4% | 3,577,267 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $99.9M | 11.2% | 4,784,674 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $96.9M | 10.8% | 10,473,913 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $71.2M | 7.97% | 3,081,307 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $62.6M | 7.00% | 1,332,545 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $53.8M | 6.02% | 14,232,751 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $37.9M | 4.24% | 1,275,552 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $32.6M | 3.64% | 2,892,663 | Common | SOLE |
| 632307104 | NTRA | NATERA INC | $31.0M | 3.46% | 700,197 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $30.4M | 3.40% | 2,000,000 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $23.3M | 2.60% | 3,400,000 | Common | SOLE |
| 26886C107 | — | EQRX INC | $22.2M | 2.48% | 10,003,573 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $17.4M | 1.95% | 15,960,588 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $15.9M | 1.78% | 3,000,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $14.3M | 1.60% | 1,822,883 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $13.6M | 1.52% | 913,969 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $13.5M | 1.51% | 915,000 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $13.5M | 1.50% | 5,701,926 | Common | SOLE |
| 56854Q200 | MRNS* | MARINUS PHARMACEUTICALS INC | $11.5M | 1.29% | 1,431,058 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $11.0M | 1.23% | 8,663,673 | Common | SOLE |
| 75340L104 | RPID | RAPID MICRO BIOSYSTEMS INC | $9.1M | 1.02% | 8,434,560 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $8.4M | 0.94% | 2,124,694 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $7.9M | 0.88% | 3,130,422 | Common | SOLE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $7.5M | 0.83% | 2,485,638 | Common | SOLE |
| 63909J108 | NAUT | NAUTILUS BIOTECHNOLOGY INC | $6.3M | 0.71% | 2,000,000 | Common | SOLE |
| 98422T100 | — | XILIO THERAPEUTICS INC | $5.9M | 0.66% | 2,805,413 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $5.5M | 0.62% | 1,408,901 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $3.3M | 0.37% | 1,937,207 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $3.1M | 0.34% | 1,642,210 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $190,000 | 0.02% | 100,000 | Common | SOLE |
| 140755109 | CARAEUR | CARA THERAPEUTICS INC | $39,725 | 0.00% | 23,646 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.